Introduction
Since the isolation of Chlamydia pneumoniae from atheroschlerotic arteria in 1990s [1[, the role of this obligate intracellular bacterium as a risk factor for atheroschlerosis has been a matter of intense debate and extensive research.
After the publication of negative results from clinical studies evaluating antibiotics as a secondary preventive medication for atheroschlerosis in early
2000s [2] , some skepticism has emerged towards the connection between C.
pneumoniae and cardiovascular diseases. However, the value of the clinical trials for proving or disproving the hypothesis is highly questionable due to the pathophysiologically late endpoints selected for the trials and the lack of complete eradication of C. pneumoniae by theused antibiotics [3] . After a transient decrease of interest in C. pneumoniae and other microbes in this context, microbial burden hypothesis has re-emerged among cardiovascular disease risk factors [4] , and the previous failures in the area will hopefully guide us to more sophisticated approaches and study designs in this respect in the future.
While the association with atheroschlerosis has received immense attention and been the subject of various human, animal and molecular level studies [5] , atheroschlerosis is not the only chronic inflammatory disease that has been linked with C. pneumoniae. As a respiratory tract pathogen, C.
pneumoniae is responsible for 5-10% of community acquired pneumonia (CAP) cases, and it is also the causative agent of various other respiratory tract illnesses with varying severity [6] . Numerous studies have evaluated the role of persistent respiratory infection by C. pneumoniae as predisposing factor in asthma and chronic obstructive pulmonary disease [7, 8] , and the well-known ability of Chlamydia spp. bacteria to disseminate into body sites distant from the primary infection via circulating white blood cells has formed the basis of the role of these pathogens also in reactive arthritis [9] . Isolation of C. pneumoniae from brain areas affected in Alzheimer's disease in post mortem samples initiated another research line focusing on the causal relationships between the bacterium and the disease also in this respect [10] .
More research is needed for achieving detailed understanding on the role of C. pneumoniae in the etiology and pathological course of these diseases.
Being able to reduce the risk of any of such prevalent illnesses could significantly alleviate the public health burden, and the idea of achieving this by eliminating C. pneumoniae has fascinated scientists in different areas within medicine. On the other hand, finding an effective chlamydiocidal agent suitable for human use would enable re-evaluation of the unanswered questions concerning causal relationships between C. pneumoniae and the above mentioned diseases and is thus of extreme importance also for evaluating the hypothesis of microbial burden in chronic disease etiology.
Collectively, these aspects form the rationale for efforts on discovering drug candidates capable of eradicating C. pneumoniae infections.
In this paper, we review the current status of attempt to discover and develop drugs against C. pneumoniae and describe recent advances in C.
pneumoniae research and technologies that are likely to have a significant impact on identifying efficacious treatments against this pathogen. In the end of the article, we highlight the key technologies and approaches we consider critical for successful generation of viable drug candidates against C.
pneumoniae. 
Challenges related to C. pneumoniae as a drug discovery target
Chlamydia pneumoniae (alternatively called Chlamydophila pneumoniae, according to the current yet not widely accepted taxonomical classification [11] is a small spherical bacterium, which is an obligate intracellular parasite.
The multiplication of the bacterium can only occur inside eukaryotic cells, in a membranous organelle detached from the host cell's endocytic vesicle system upon the bacterium's entry into the cell. In Figure 1 the life cycle of C.
pneumoniae is presented as a schematic illustration. As other gram-negative bacteria, the outermost structure of C. pneumoniae itself is a lipopolysaccharide (LPS) -rich outer membrane, which poses significant challenges for drug penetration. In general the outer membrane is the primary reason for inherent resistance of gram-negative bacteria towards various antibacterial agents, and in the case of C. pneumoniae, additional permeability barriers are formed by host cell plasma membrane and the inclusion membrane surrounding the bacterium in its replicating (RB) form.
Any compound targeting proteins or other components within RBs must thus be able to penetrate all these membranes in order to reach its target site. One strategy to overcome such challenges posed to the physicochemical properties of antichlamydial compounds is to focus on targeting components not residing inside the inclusion membrane, such as host cell factors or chlamydial effector proteins attached to the inclusion membrane or secreted to the host cell cytoplasm.
While the extracellular, non-dividing form of the bacterium, referred as elementary body (EB), is rigid and osmotically stable, the intracellular replicating form (reticulate body, RB) lacks the structural components required for such integrity. The dramatic changes in rigidity and osmostability between EB and RB reflect the unique structure of the bacterium's cell wall, which contains only very marginal amounts of peptidoglycan [12] . Instead, the EB form maintains its structure by disulfide bridged protein complexes, which are released as separate protein molecules upon EB differentiation into RB after entry to a host cell [13] [14] [15] . Within RB to EB maturation and exit of the newly formed bacteria from the host cell, disulfide bonds are re-formed. These features explain the resistance of C. pneumoniae and other Chlamydia spp.
bacteria to antibiotics targeting bacterial cell wall biosynthesis, and in fact, penicillins are known to trigger the development of persistent infection rather than leading to effective eradication [16, 17] .
Propensity to persistence is the hallmark of chlamydial infections that forms the most obvious challenges in antichlamydial therapy. This viable but non-replicating state, known to be induced by a spectrum of environmental factors, is characterized by a specific intracellular form known as aberrant body (AB) (Figure 1 ). Chlamydial persistence, along with the factors triggering it and the consequences of this infection state have been extensively reviewed in the literature over the past decades [18] [19] [20] ., and it is generally accepted that despite their low or non-existing multiplication rate, the bacteria residing in ABs maintain active metabolism and continue to manipulate their host cell by secreting effector proteins interfering with host structures and signaling pathways [21] . Considering antibacterial therapy, the persistent infection is not sensitive to antibiotics affecting bacterial replication machinery, However, as discussed below, the recent advances in inserting C. trachomatis derived plasmid into C. pneumoniae [23] as well as producing mutant strains of related bacterial species shed some hope on overcoming these major limitations also with C. pneumoniae in the future.
C. pneumoniae has an established role as a causative agent in atypical pneumonia and other respiratory infections, but according to recent findings it may not be the only chlamydia-related pathogen associated with such a disease. Since the discovery of novel families Parachlamydiaceae, Simkaniaceae and Waddliaceae within the order Chlamydiales more than 10 years ago [24, 25] , accumulating evidence has indicated that these chlamydia related bacteria possess a broad host range and may be associated with respiratory tract infections also in humans. PCR studies have reported the prevalences between 1 to 10% of these species in human respiratory samples [26, 27] , and preliminary susceptibility studies have indicated that some of the newly discovered species are not sensitive to quinolones which are often used for treat atypical pneumonia [28] . As soon as our understanding increases concerning the relevance of these species as causative agents of human infections, it may change also the requirements of an effective therapeutic agent aimed for the treatment of atypical respiratory pneumonia.
Existing antibiotic therapies
Current treatment strategies for chlamydial infections have recently been reviewed by Hammerschlag and Kohloff [29] . C. pneumoniae is generally considered susceptible to antibiotics interfering with prokaryotic DNA, RNA or protein synthesis, such as quinolones, tetracyclines and macrolides, but in contrast to C. trachomatis, not sensitive to trimethoprim or sulfonamides [29, 30] . Furthermore, aminoglycosides are not useful in treating Chlamydia infections since they fail to penetrate eukaryotic cell membranes. In most countries, the recommended antibiotic therapy involves the use of azithromycin. However, even though azithromycin and several other antibiotics effectively eradicate C. pneumoniae infection in most cell types, including epithelial cells which are most often used for in vitro susceptibility testing, the infection in peripheral blood mononuclear cells (PBMNC) is refractory to antibiotics and treatment failures have been reported even after prolonged azithromycin therapy [23, 31] . In clinical settings, another therapyrelated challenge is the widespread use of penicillins for treating respiratory tract infections. Emergence of beta-lactam resistant strains of Streptococcus pneumoniae and other common respiratory pathogens has shifted the CAP treatment guidelines to more common use of quinolones [32] , but beta-lactam pneumoniae contribute to its popularity as primary screening target, but it is, however, good to remember that despite the relatively close phylogenetic relationship between the two species some major differences in their susceptibility as antibacterial agents are known to exist [29, 43] . pneumonia, and assaying the currently used drugs either alone or as combinations should be further encouraged. 
Targeting type 3 secretion system

Drug design based on in silico data
To date,only a few crystal structures of C. pneumoniae proteins have been Given the lack of structural data on actual C. pneumoniae proteins, sequence data has been successfully used for homologue-based approaches.
Full genomes of several C. pneumoniae strains have been sequenced and comparative bioinformatics studies can thus be applied to improve our understanding of chlamydial proteins having homologues in other species.
This approach has been successfully followed for the identification of C.
pneumoniae growth inhibitors by conducting a virtual screen with a RNA methyltransferase structure from Bacillus subtilis, which has highly similar amino acid sequence to that of the C. pneumoniae dimethyladenosine pneumoniae isolate CV-6 were identified as the most potent antichlamydial compounds containing 2-arylbenzimidazole scaffold. The main finding from conformation studies of 2-arylbenzimidazoles was that compounds which can more easily adopt a non-planar conformation show higher antichlamydial 
Omics approaches
Besides comparative genomics studies, C. pneumoniae genome sequencing has provided the basis for transcriptional analysis studies on whole genome Besides the protein expression levels, it is generally accepted that also translocation of the C. pneumoniae proteins are tightly regulated in each stage of its life cycle, but analysis on these processes in whole proteome level has been limited by inability to isolate host cell cytoplasm without rupturing the chlamydial inclusions. However, comparative analysis on host cell cytoplasm samples and isolated bacteria has been successfully used for identification of C. pneumoniae effector proteins, identifying for example the relatively well- identifying a cleavage site of the relatively well studied chlamydial secretory protease-like activity factor [81] . and C. pneumoniae is the absence of this 7.5 kb plasmid [endogenous to most C. trachomatis strains) from C. pneumoniae. However, the first report on delivering the plasmid artificially into C. pneumoniae has newly been described [23] .
Even though most of the newly described techniques may not directly enable targeted C. pneumoniae mutant generation, they are expected to have a deep impact on the molecular level studies of related chlamydial species and will therefore improve our understanding on the biology of also C.
pneumoniae via comparative genetic analyses.
Expert Opinion
During the past decade, our understanding on the biology of C. pneumoniae infections has dramatically increased, and potential molecular targets for therapeutic intervention have been suggested based on molecular biology, in silico and omics studies. Inspired by both bacteria host cell interaction studies and the general trends in intracellular pathogen therapy approaches, such targets could include both C. pneumoniae and host cell proteins. These proteins have not, however, been subjected to comprehensive target antibiotics. In fact, many compound groups presented in Table 1 as well as several approved drugs mentioned in this review are of natural product origin supporting the relevance of this view also in the case of antichlamydial drug discovery. The major therapeutic challenge of C. pneumoniae infections is the persistent infection. Prolonged treatment with broad-spectrum antibiotics is needed for complete eradication of the bacterium, and treatment failures have been reported even after extensive antibiotic treatment [22] . Yet it might be theoretically possible to find a chemical agent capable of eradicating the persistent infection after single dose or short-time treatment, the more realistic scenario is that patients would be treated for weeks if not months with the therapeutic agent. Two major obstacles prevent the use of currently available antibiotics for this purpose: adverse effects on host normal microbiota and the risk of antimicrobial resistance. To minimize both risks, a Chlamydia-specific or selective agent would be highly desirable. None of the antibiotics in current use bear such a feature, as Chlamydia has never been the primary target of industrial antibiotic discovery campaigns but has rather been assayed as one minor group among others within antibiotic spectrum determination. While most efforts in antibiotic discovery in past decades have been put on screening for broad-spectrum agents, focusing on more narrow-spectrum compounds has been suggested as one success factor in tomorrow's antibacterial drug discovery [88] . As regards to C. pneumoniae, finding a specific or selective inhibitor can be considered a realistic goal given the phylogenetically distinct nature of these bacteria and the unique feature related to it. The second half of the issue is choosing the indication of the potential new drug to be developed. Targeting C. pneumoniae alone may be considered as too narrow indication by regulatory authorities. Atypical pneumonia, on the other hand, could be considered as an indication, thus 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w  O  n  l  y 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 • Microbial burden theory is the motivation for the attempts on discovering C. pneumoniae specific antibiotics.
• Lack of validated targets and general trends in bioactivity screening support phenotypic assays for hit/lead discovery.
• Nature of the bacterium poses particular demands on the physicochemical properties of the chemical libraries, favoring natural products.
• Evaluation of antichlamydial properties of clinically approved drugs alone and in combinations offers one strategy for decreasing the bacterial burden.
• Omics techniques and genetic tools are expected to provide means for validating bacterial and host cell targets for chemical intervention. Chlamydia species, but details on C. pneumoniae exit have not been studied.
In principle, any of the devekiomental phases can be targeted with antichlamydial compounds. Conventional antibiotics mostly target the multiplication phase, which may not, however, represent the optimal target since it easily triggers persistence.
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